Cargando…

Challenges facing the clinical adoption of a new prognostic biomarker: a case study

In this article, we show how a particular biomarker comes into being in an emergency department in a hospital in Copenhagen, Denmark. We explore the contextual becoming of this biomarker, suPAR, through interviews with nurses and physicians and through relational ontology. We find that as a prognost...

Descripción completa

Detalles Bibliográficos
Autores principales: Larsen, Trine Schifter, Eugen-Olsen, Jesper, Andersen, Ove, Kirk, Jeanette Wassar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Palgrave Macmillan UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9860228/
https://www.ncbi.nlm.nih.gov/pubmed/36713027
http://dx.doi.org/10.1057/s41292-022-00296-2
_version_ 1784874533886361600
author Larsen, Trine Schifter
Eugen-Olsen, Jesper
Andersen, Ove
Kirk, Jeanette Wassar
author_facet Larsen, Trine Schifter
Eugen-Olsen, Jesper
Andersen, Ove
Kirk, Jeanette Wassar
author_sort Larsen, Trine Schifter
collection PubMed
description In this article, we show how a particular biomarker comes into being in an emergency department in a hospital in Copenhagen, Denmark. We explore the contextual becoming of this biomarker, suPAR, through interviews with nurses and physicians and through relational ontology. We find that as a prognostic biomarker suPAR is challenged in it becoming as an object for clinical practice in the emergency department by the power of diagnostic practices and the desire for experience-based scripts that quickly enable the clinician to reach the right diagnosis. Although suPAR is enacted as a promising triage strategy suggesting a low or high risk of disease, the inability to rule out specific diagnoses and producing the notion of secure clinical actions make its non-specificity and prognostic character problematic in clinical practices. Specific diagnostic criteria versus prognostic interpretation and non-specificity risk profiling challenges the way healthcare workers in an emergency department understand the tasks they are set to solve and how to solve them. We discuss how the becoming of suPAR is strengthened through enactments of specificity and engagement in triage strategies and we reflect on it’s becoming through new diagnostic practices with the need to accommodate diagnostic ambiguity.
format Online
Article
Text
id pubmed-9860228
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Palgrave Macmillan UK
record_format MEDLINE/PubMed
spelling pubmed-98602282023-01-23 Challenges facing the clinical adoption of a new prognostic biomarker: a case study Larsen, Trine Schifter Eugen-Olsen, Jesper Andersen, Ove Kirk, Jeanette Wassar Biosocieties Original Article In this article, we show how a particular biomarker comes into being in an emergency department in a hospital in Copenhagen, Denmark. We explore the contextual becoming of this biomarker, suPAR, through interviews with nurses and physicians and through relational ontology. We find that as a prognostic biomarker suPAR is challenged in it becoming as an object for clinical practice in the emergency department by the power of diagnostic practices and the desire for experience-based scripts that quickly enable the clinician to reach the right diagnosis. Although suPAR is enacted as a promising triage strategy suggesting a low or high risk of disease, the inability to rule out specific diagnoses and producing the notion of secure clinical actions make its non-specificity and prognostic character problematic in clinical practices. Specific diagnostic criteria versus prognostic interpretation and non-specificity risk profiling challenges the way healthcare workers in an emergency department understand the tasks they are set to solve and how to solve them. We discuss how the becoming of suPAR is strengthened through enactments of specificity and engagement in triage strategies and we reflect on it’s becoming through new diagnostic practices with the need to accommodate diagnostic ambiguity. Palgrave Macmillan UK 2023-01-21 /pmc/articles/PMC9860228/ /pubmed/36713027 http://dx.doi.org/10.1057/s41292-022-00296-2 Text en © The Author(s), under exclusive licence to Springer Nature Limited 2023, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Original Article
Larsen, Trine Schifter
Eugen-Olsen, Jesper
Andersen, Ove
Kirk, Jeanette Wassar
Challenges facing the clinical adoption of a new prognostic biomarker: a case study
title Challenges facing the clinical adoption of a new prognostic biomarker: a case study
title_full Challenges facing the clinical adoption of a new prognostic biomarker: a case study
title_fullStr Challenges facing the clinical adoption of a new prognostic biomarker: a case study
title_full_unstemmed Challenges facing the clinical adoption of a new prognostic biomarker: a case study
title_short Challenges facing the clinical adoption of a new prognostic biomarker: a case study
title_sort challenges facing the clinical adoption of a new prognostic biomarker: a case study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9860228/
https://www.ncbi.nlm.nih.gov/pubmed/36713027
http://dx.doi.org/10.1057/s41292-022-00296-2
work_keys_str_mv AT larsentrineschifter challengesfacingtheclinicaladoptionofanewprognosticbiomarkeracasestudy
AT eugenolsenjesper challengesfacingtheclinicaladoptionofanewprognosticbiomarkeracasestudy
AT andersenove challengesfacingtheclinicaladoptionofanewprognosticbiomarkeracasestudy
AT kirkjeanettewassar challengesfacingtheclinicaladoptionofanewprognosticbiomarkeracasestudy